HCC

Efficacy, safety, and quality of life data from IMbrave150 have changed the standard of care for unresectable hepatocellular carcinoma.

Recent updates from the IMbrave150 study, which led to the FDA approval of frontline atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma [HCC].

Richard S. Finn, MD, provides an overview of the systemic treatment options for advanced unresectable hepatocellular carcinoma.

Defining resectability in hepatocellular carcinoma based on burden of liver disease and Child-Pugh score.

A review of prognostic factors and the importance of understanding underlying liver disease to help stage and treat patients with hepatocellular carcinoma.

Richard S. Finn, MD, provides insight on the key risk factors that lead to hepatocellular carcinoma.

Data are reviewed from the phase 3 IMbrave150 trial for unresectable hepatocellular carcinoma.

Unique challenges and opportunities for the treatment and management of patients with hepatocellular carcinoma have been identified by the Association of Community Cancer Centers in an analysis.

Al B. Benson, MD, discusses recent developments for the treatment of patient with hepatocellular carcinoma with systemic therapy in the first and second line.

New data showed the Helio Liver Test demonstrated high accuracy and screening value of this cell-free DNA methylation blood-based assay for the detection of hepatocellular carcinoma.

Laura M. Kulik, MD, talked through diagnosing a 77-year-old female patients with hepatocellular carcinoma as well as the treatment options for her disease during a Targeted Oncology Case Based Peer Perspectives event.

An in-depth discussion on the targeting of specific molecular pathways with newer, novel therapies to better manage patients with liver cancer.

Ghassan K. Abou-Alfa, MD, discusses the therapies being used to treat patients with hepatocellular carcinoma right now.